Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems

Table 2

Studies of switch towards more lipid-friendly antiretroviral regimens and variations in total and fractionated cholesterol and triglyceride blood levels.

Author	Year	Study drug	Switched drug	Design	Patients (𝑛)	F-up (wks)	∆ TC (mmol/L)	∆HDL (mmol/L)	∆LDL (mmol/L)	∆ TG (mmol/L)
Negredo [34]	2002	Nevirapine Efavirenz	PIs	Randomized	77	48	𝑃<.05; only Nev.	NA	NA	𝑃<.05; only Nev.
Petit [35]	2004	Nevirapine	PIs	Observational	55	24	NA	+0,2; (𝑃=.01)	NA	−0,36; (𝑃=.02)
Ward [36]	2006	Nevirapine	Efavirenz	Retrospective	40	106	−0,18; (𝑃<.05)	+0,05; (𝑃<.05)	−0,25; (𝑃<.05)	−0,70; (𝑃<.05)
Parienti [37]	2007	Nevirapine	Efavirenz	Randomized	36	52	NA	𝑃<.04	NA	NA
Gonzalez-Tome [38]	2008	Nevirapine	PIs	Pediatric, case-series	7	52	−0,7; (𝑃=.09)	+0,5; (𝑃=.03)	stable	NA
Katlama [39]	2003	Abacavir	PIs	Randomized	209	48	𝑃<.001	NA	NA	𝑃=.006
Keiser [40]	2005	Abacavir	PIs	Randomized	104	28	−0,82; (𝑃<.001)	NA	−0,49; (𝑃=.02)	−1,1; (𝑃=.02)
Soriano [41]	2005	Atazanavir^a	PIs	Randomized	189	48	−0,4; (𝑃<.001)	NA	NA	−0,9; (𝑃<.001)
Gatell [42]	2007	Atazanavir/r	PIs	Randomized	419	48	𝑃<.001	𝑃<.001	NA	𝑃<.001
Mallolas [44]	2009	Atazanavir/r	PIs	Randomized	248	48	−0,4; (𝑃<.001)	NA	NA	−0,5; (𝑃<.001)
Llibre [43]	2006	TDF	Stavudine	Retrospective	352	48	−0,4; (𝑃<.001)	NA	−0,2; (𝑃<.001)	−0,4; (𝑃<.001)
Schewe [44]	2006	TDF	Stavudine	Retrospective	66	130	−0,98; (𝑃=.002)	NA	NA	NA
Madruga [45]	2007	TDF	Stavudine	Randomized	85	144	−0,6; (𝑃<.0001)	NA	NA	−0,9; (𝑃<.0001)
Valantin [46]	2010	TDF/FTC	NRTIs	Randomized	91	12	NA	NA	−0,4; (𝑃=.03)	−0,4; (𝑃=.03)
Eron [41]	2010	Raltegravir	Lopinavir/r	Randomized	707	12	−12,6%; (𝑃<.0001)	NA	−15%; (𝑃<.0001)	−42,2%; (𝑃<.0001)

a49 patients switched to unboosted atazanavir, 53 to atazanavir/r.